Literature DB >> 7554377

Epitope mapping of anti-proteinase 3 and anti-myeloperoxidase antibodies.

L Chang1, S Binos, J Savige.   

Abstract

Anti-proteinase 3 (PR3) and anti-myeloperoxidase (MPO) autoantibodies are present in many patients with Wegener's granulomatosis (WG) and microscopic polyarteritis. The aim of this study was to determine whether these antibodies bound to linear peptide sequences on their target antigens. If common linear epitopes were demonstrated, then these could be manufactured and used in diagnostic ELISAs for anti-PR3 and anti-MPO antibodies. In addition, any homology between these epitopes and bacterial or viral sequences might implicate those microorganisms in the development of these antibodies and the pathogenesis of the associated diseases. The presence of linear epitopes on PR3 and MPO was suggested by the binding of the corresponding autoantibodies to these proteins after they had been reduced with beta-mercaptoethanol (beta-ME) and denatured with SDS or boiling, and digested with proteases. Four of the 22 sera with anti-PR3 antibodies bound to PR3 in Western blots after treatment with SDS, beta-ME and boiling for 5 min. Thermal denaturation reduced the amount of binding more than other forms of denaturation. One serum with anti-PR3 antibodies bound to Lys-C and Glu-C-digested PR3 in dot blots. Linear epitopes could not be further defined by their binding in an ELISA using overlapping peptides corresponding to the PR3 molecule because of non-specific binding. Three of the five sera with anti-MPO antibodies bound to MPO in Western blots after treatment with SDS, beta-ME and boiling for 5 min. One serum with anti-MPO antibodies bound to Lys-C and Glu-C-digested MPO in dot blots. Again, linear epitopes could not be further defined using an ELISA with overlapping peptides because of non-specific binding. Some anti-PR3 and anti-MPO antibodies are likely to recognize linear epitopes, but these cannot be defined by use of a PIN ELISA system.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7554377      PMCID: PMC1553353          DOI: 10.1111/j.1365-2249.1995.tb06644.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  21 in total

1.  Antineutrophil cytoplasmic autoantibodies in Wegener's granulomatosis recognize conformational epitope(s) on proteinase 3.

Authors:  P Bini; J E Gabay; A Teitel; M Melchior; J L Zhou; K B Elkon
Journal:  J Immunol       Date:  1992-08-15       Impact factor: 5.422

2.  Strategies for epitope analysis using peptide synthesis.

Authors:  H M Geysen; S J Rodda; T J Mason; G Tribbick; P G Schoofs
Journal:  J Immunol Methods       Date:  1987-09-24       Impact factor: 2.303

3.  In vitro proliferative responses and antibody titers specific to human acetylcholine receptor synthetic peptides in patients with myasthenia gravis and relation to HLA class II genes.

Authors:  S Brocke; C Brautbar; L Steinman; O Abramsky; J Rothbard; D Neumann; S Fuchs; E Mozes
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

4.  Molecular mimicry and autoimmune disease.

Authors:  M B Oldstone
Journal:  Cell       Date:  1987-09-11       Impact factor: 41.582

5.  Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology?

Authors:  D J Davies; J E Moran; J F Niall; G B Ryan
Journal:  Br Med J (Clin Res Ed)       Date:  1982 Aug 28-Sep 4

6.  Epitopes on proteinase-3 recognized by antibodies from patients with Wegener's granulomatosis.

Authors:  R C Williams; R Staud; C C Malone; J Payabyab; L Byres; D Underwood
Journal:  J Immunol       Date:  1994-05-01       Impact factor: 5.422

7.  Interference of Wegener's granulomatosis autoantibodies with neutrophil Proteinase 3 activity.

Authors:  B A van de Wiel; K M Dolman; C H van der Meer-Gerritsen; C E Hack; A E von dem Borne; R Goldschmeding
Journal:  Clin Exp Immunol       Date:  1992-12       Impact factor: 4.330

8.  Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis.

Authors:  F J van der Woude; N Rasmussen; S Lobatto; A Wiik; H Permin; L A van Es; M van der Giessen; G K van der Hem; T H The
Journal:  Lancet       Date:  1985-02-23       Impact factor: 79.321

9.  Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis.

Authors:  R J Falk; J C Jennette
Journal:  N Engl J Med       Date:  1988-06-23       Impact factor: 91.245

Review 10.  Use of synthetic peptides for the detection and quantification of autoantibodies.

Authors:  K B Elkon
Journal:  Mol Biol Rep       Date:  1992-06       Impact factor: 2.316

View more
  15 in total

1.  Characterization of monoclonal antibodies to proteinase 3 (PR3) as candidate tools for epitope mapping of human anti-PR3 autoantibodies.

Authors:  Y M Van Der Geld; P C Limburg; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

2.  A comparison of the characteristics of circulating anti-myeloperoxidase autoantibodies in vasculitis with those in non-vasculitic conditions.

Authors:  I C Locke; B Leaker; G Cambridge
Journal:  Clin Exp Immunol       Date:  1999-02       Impact factor: 4.330

3.  Anti-proteinase-3 (PR3) antibodies (C-ANCA) recognize various targets on the human umbilical vein endothelial cell (HUVEC) membrane.

Authors:  M De Bandt; O Meyer; L Dacosta; C Elbim; C Pasquier
Journal:  Clin Exp Immunol       Date:  1999-02       Impact factor: 4.330

4.  Anti-neutrophil cytoplasmic antibodies (ANCA) from patients with systemic vasculitis recognize restricted epitopes of proteinase 3 involving the catalytic site.

Authors:  M E Griffith; A Coulthart; S Pemberton; A J George; C D Pusey
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

5.  Discrimination and variable impact of ANCA binding to different surface epitopes on proteinase 3, the Wegener's autoantigen.

Authors:  Francisco Silva; Amber M Hummel; Dieter E Jenne; Ulrich Specks
Journal:  J Autoimmun       Date:  2010-12       Impact factor: 7.094

6.  A proportion of proteinase 3 (PR3)-specific anti-neutrophil cytoplasmic antibodies (ANCA) only react with PR3 after cleavage of its N-terminal activation dipeptide.

Authors:  J Sun; D N Fass; M A Viss; A M Hummel; H Tang; H A Homburger; U Specks
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

Review 7.  B cell epitope specificity in ANCA-associated vasculitis: does it matter?

Authors:  Y M van der Geld; C A Stegeman; C G M Kallenberg
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

8.  Epitope shift of proteinase-3 anti-neutrophil cytoplasmic antibodies in patients with small vessel vasculitis.

Authors:  D Selga; M Segelmark; L Gunnarsson; T Hellmark
Journal:  Clin Exp Immunol       Date:  2010-01-06       Impact factor: 4.330

9.  Epitope mapping of anti-PR3 antibodies using chimeric human/mouse PR3 recombinant proteins.

Authors:  D Selga; M Segelmark; J Wieslander; L Gunnarsson; T Hellmark
Journal:  Clin Exp Immunol       Date:  2004-01       Impact factor: 4.330

10.  The binding of proteinase 3 antineutrophil cytoplasmic antibodies (PR3-ANCA) varies in different ELISAs.

Authors:  M Trevisin; P Neeson; J Savige
Journal:  J Clin Pathol       Date:  2004-03       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.